While the best thing to do with cancer cells is to kill them, the next best thing is to prevent them from growing. Chemotherapies often arrest their growth, forcing tumor cells into senescence.
Scientists have identified antibodies that stimulated bone marrow cells to differentiate into microglia-like cells and migrate to the brain, where they reduced the levels of amyloid plaque in mouse models of Alzheimer's disease.
Buoyed by strong scientific evidence and subtle hints of success in clinical trials, the search continues for disease-modifying therapies for Alzheimer's disease (AD) that target amyloid-beta.
Whether it's perseverance or perseveration remains to be seen. But between the strong scientific evidence implicating amyloid beta in Alzheimer's disease (AD) and evidence of some progress in clinical trials, neither industry nor academia is willing to call it quits on pursuing amyloid beta as a target.
When they are directed against the wrong targets, immunoglobulin gamma (IgG) antibodies are the drivers of many autoimmune disorders. But high-dose IgG antibodies are also used to resolve inflammation.
